Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for ONL Therapeutics

    Client Virtual Booth

    ONL THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ONL Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    PO Box 131547 Ann Arbor, MI 48113
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.onltherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/onl-therapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
    ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference

    https://www.globenewswire.com//news-release/2024/02/06/2824169/0/en/ONL-Therapeutics-to-Present-at-2024-BIO-CEO-Investor-Conference.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    ONL Therapeutics to Present on ONL1204 in Podium Presentation
    ONL Therapeutics to Present on ONL1204 in Podium Presentation

    https://www.globenewswire.com//news-release/2024/01/23/2813952/0/en/ONL-Therapeutics-to-Present-on-ONL1204-in-Podium-Presentation-at-the-47th-Annual-Meeting-of-the-Macula-Society.html

    GLOBENEWSWIRE
    23 Jan 2024
    Share Share
    ONL Therapeutics Completes Enrollment in Ph2 Study First-in-Class Fas-Inhibitor
    ONL Therapeutics Completes Enrollment in Ph2 Study First-in-Class Fas-Inhibitor

    https://www.globenewswire.com/news-release/2023/08/28/2732482/0/en/ONL-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-First-in-Class-Fas-Inhibitor-in-Patients-with-Macula-Off-Rhegmatogenous-Retinal-Detachment.html

    GLOBENEWSWIRE
    28 Aug 2023
    Share Share
    ONL Announces First Patient Dosed in PII Trial of First-in-Class Fas-Inhibitor
    ONL Announces First Patient Dosed in PII Trial of First-in-Class Fas-Inhibitor

    https://www.globenewswire.com/news-release/2023/04/12/2645181/0/en/ONL-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-First-in-Class-Fas-Inhibitor-in-Patients-with-Macula-Off-Rhegmatogenous-Retinal-Detachment.html

    GLOBENEWSWIRE
    12 Apr 2023
    Share Share
    ONL Therapeutics to Report Data on ONL1204 in Podium Presentation at ARVO
    ONL Therapeutics to Report Data on ONL1204 in Podium Presentation at ARVO

    https://www.globenewswire.com/news-release/2023/04/11/2644229/0/en/ONL-Therapeutics-to-Report-Clinical-Data-on-ONL1204-in-Podium-Presentation-at-the-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html

    GLOBENEWSWIRE
    11 Apr 2023
    Share Share
    ONL Therapeutics Closes First Tranche of $15 Million Series C Financing
    ONL Therapeutics Closes First Tranche of $15 Million Series C Financing

    https://www.globenewswire.com/news-release/2023/03/08/2622887/0/en/ONL-Therapeutics-Closes-First-Tranche-of-15-Million-Series-C-Financing-to-Advance-Lead-Compound-into-Phase-2-Clinical-Trial.html

    GLOBENEWSWIRE
    08 Mar 2023
    Share Share
    ONL Therapeutics to Present at Biennial Meeting of the International Society
    ONL Therapeutics to Present at Biennial Meeting of the International Society

    https://www.globenewswire.com/news-release/2023/02/13/2606500/0/en/ONL-Therapeutics-to-Present-at-the-XXVth-Biennial-Meeting-of-the-International-Society-for-Eye-Research.html

    GLOBENEWSWIRE
    13 Feb 2023
    Share Share
    ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
    ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference

    https://www.globenewswire.com/news-release/2023/02/02/2600334/0/en/ONL-Therapeutics-to-Present-at-2023-BIO-CEO-Investor-Conference.html

    GLOBENEWSWIRE
    02 Feb 2023
    Share Share
    ONL Receive FDA Clearance of Investigational NDA for ONL1204 Ophthalmic Solution
    ONL Receive FDA Clearance of Investigational NDA for ONL1204 Ophthalmic Solution

    https://www.globenewswire.com/news-release/2023/02/01/2599296/0/en/ONL-Therapeutics-Receives-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-ONL1204-Ophthalmic-Solution.html

    GLOBENEWSWIRE
    01 Feb 2023
    Share Share
    ONL to Highlight Data in Presentations at 46th Annual Macula Society Meeting
    ONL to Highlight Data in Presentations at 46th Annual Macula Society Meeting

    https://www.globenewswire.com/news-release/2023/01/26/2595900/0/en/ONL-Therapeutics-to-Highlight-New-Data-in-Upcoming-Scientific-Presentations-at-the-46th-Annual-Macula-Society-Meeting-and-the-XXVth-Biennial-Meeting-of-the-International-Society-fo.html

    GLOBENEWSWIRE
    26 Jan 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search